Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-10-21
Monoclonal Antibodies Active Trials in China
As of 2026-10-21, there are 14 active clinical trials investigating Monoclonal Antibodies for multiple myeloma across 27 provinces and 200 study centers in China. Monoclonal antibodies bind a single antigen on the myeloma cell surface — CD38 being the dominant target in China — and eliminate tumour cells through antibody-dependent cytotoxicity and complement activation. They are a common backbone in both frontline and relapsed regimens.
Active Trials
14
Provinces
27
Centers
200
Active Studies (14)
Population synthesized by CMDNShowing 14 published English records of 14 registry trials.
Phase IIICTR20253414
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone Versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Novel monoclonal antibody targeting CD38
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute & Hospital 等 78 家中心
Phase ICTR20254167
RecruitingA Randomized, Double-Blind, Parallel-Controlled Study Comparing the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of JY43 and Darzalex® in Healthy Male Participants
Target Population: Healthy volunteer
Target: Daratumumab biosimilar (monoclonal antibody)
Study Sites: Beijing Gobroad Hospital、PKU Healthcare Luzhong Hospital
Phase IIICTR20241656
RecruitingA Randomized Controlled Phase III Clinical Study of Equecabtagene Autoleucel Injection in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: CAR-T
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Ruijin Hospital, Shanghai Jiao Tong University School of Medicine、Peking Union Medical College Hospital, Chinese Academy of Medical Sciences 等 28 家中心
Phase IIICTR20241434
RecruitingA Phase III, Randomized Study Comparing Teclistamab in Combination With Subcutaneous (SC) Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With SC Daratumumab and Lenalidomide (Tal-DR) Versus SC Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Not Eligible or Not Planned for Autologous Stem Cell Transplantation as Initial Therapy
Target Population: Newly diagnosed
Target: BCMA × CD3 bispecific antibody (MajestTEC-7 study)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、Henan Cancer Hospital、Sun Yat-sen University Cancer Center 等 32 家中心
Phase ICTR20230879
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KYS202002A Monoclonal Antibody Injection in Patients with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Beijing Chaoyang Hospital, Capital Medical University、Shengjing Hospital of China Medical University、Zhongshan Hospital, Fudan University、Sun Yat-sen University Cancer Center 等 7 家中心
Phase Ib/IICTR20252876
RecruitingAn Open-Label, Multicenter Phase Ib/II Clinical Trial Evaluating the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR1803 Injection in Combination with an Anti-CD38 Monoclonal Antibody in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received at Least 1 Prior Line of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Target Population: Relapsed/refractory
Target: Novel bispecific antibody targeting BCMA (GR1803)
Study Sites: The First Affiliated Hospital of Xi'an Jiaotong University、Shanghai Fourth People's Hospital Affiliated to Tongji University、Xiangya Hospital Central South University
Phase IICTR20231956
RecruitingAn International, Multicenter, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Continue to Benefit From an Isatuximab-Based Treatment Following Completion of a Phase I, II, or III Parent Study
Target Population: Multiple myeloma
Target: Anti-CD38 monoclonal antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Royal North Shore Hospital、Instituto COI de Educacao e Pesquisa、James Lind Centro de investigacion del cancer 等 21 家中心
Phase ICTR20244043
RecruitingA Phase I Clinical Study Evaluating the Tolerability and Pharmacokinetics of TQB2029 for Injection in Participants with Multiple Myeloma
Target Population: Relapsed/refractory
Target: Bispecific antibody targeting GPRC5D×CD3
Study Sites: West China Hospital, Sichuan University、Zhongshan Hospital, Fudan University、Jiangsu Province Hospital、Anhui Provincial Hospital 等 12 家中心
Phase IIICTR20260453
RecruitingA Multicenter, Open-label, Randomized Phase III Clinical Trial Comparing the Efficacy and Safety of GR1803 Injection Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received 1-3 Prior Lines of Therapy (Including Lenalidomide and a Proteasome Inhibitor)
Target Population: Relapsed/refractory
Target: BCMA-targeting bispecific antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology、Henan Cancer Hospital、Shengjing Hospital of China Medical University 等 67 家中心
Phase ICTR20260785
RecruitingA Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetic Profile, Safety, Tolerability, and Immunogenicity of HLX15-SC Versus DARZALEX FASPRO; Combined with Lenalidomide-Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation
Target Population: Newly diagnosed
Target: Recombinant fully human anti-CD38 monoclonal antibody
Study Sites: Zhongshan Hospital, Fudan University、Peking University Third Hospital、Guangzhou First People's Hospital、The Third Hospital of Hebei Medical University 等 66 家中心
Phase I/IICTR20233843
RecruitingA Multicenter, Open-label, Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CM313(SC) Injection as Monotherapy and in Combination with Other Antineoplastic Therapies in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Target Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Hunan Cancer Hospital 等 16 家中心
Phase IIICTR20242452
RecruitingA Phase III, Multicenter, Randomized, Open-Label Study Comparing Etentamig with Available Standard of Care Therapies in Participants with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
Target Population: Relapsed/refractory
Target: BCMA × CD3 bispecific T-cell engager (BiTE)
Study Sites: The First Affiliated Hospital of Nanchang University、Shanghai Tongji Hospital、Sun Yat-sen University Cancer Center、Henan Cancer Hospital 等 19 家中心
Phase IIICTR20241042
RecruitingA Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of SG301 Injection Combined with Pomalidomide and Dexamethasone versus Placebo Combined with Pomalidomide and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma (Stage 1)
Target Population: Relapsed/refractory
Target: Recombinant humanized anti-CD38 monoclonal antibody
Study Sites: The First Affiliated Hospital of Soochow University、Beijing Chaoyang Hospital, Capital Medical University、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology、Tianjin Medical University Cancer Institute and Hospital 等 12 家中心
Phase ICTR20260125
RecruitingA Phase I, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HL17 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Recombinant anti-BCMA and CD3 bispecific antibody injection
Study Sites: PKU Healthcare Luzhong Hospital